Q4 2023 · 13F-HR
Logos Global Management LPholdings as filed
Filed 2024-02-14 · accession 0001172661-24-001344
$1.07B
Reported value
53
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 23282W605 | CYTK | CYTOKINETICS INC | $135.7M | 12.7% | 1,625,000 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $67.5M | 6.30% | 700,000 | CALL | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $64.0M | 5.98% | 1,800,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $59.9M | 5.59% | 1,000,000 | CALL | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $56.9M | 5.31% | 950,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $55.2M | 5.15% | 145,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $54.4M | 5.08% | 4,383,875 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $50.6M | 4.72% | 1,200,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $43.6M | 4.07% | 1,070,058 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $38.2M | 3.57% | 1,275,000 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $35.3M | 3.30% | 568,173 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $29.9M | 2.79% | 2,100,000 | Common | SOLE |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $28.5M | 2.66% | 90,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $27.3M | 2.55% | 400,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $25.0M | 2.33% | 1,880,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $22.5M | 2.10% | 4,950,000 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX INC | $19.0M | 1.77% | 500,000 | CALL | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $18.7M | 1.74% | 800,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $17.8M | 1.67% | 4,000,000 | Common | SOLE |
| 617760202 | MOR2 | MORPHOSYS AG | $14.6M | 1.36% | 1,475,000 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $13.3M | 1.24% | 5,032,501 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $13.1M | 1.22% | 600,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $10.4M | 0.97% | 950,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $10.0M | 0.94% | 350,000 | Common | SOLE |
| 617760202 | MOR2 | MORPHOSYS AG | $9.9M | 0.92% | 1,000,000 | CALL | SOLE |
| 00445A100 | — | ACELYRIN INC | $9.3M | 0.87% | 1,250,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $9.1M | 0.85% | 150,000 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $8.2M | 0.77% | 5,850,000 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $8.1M | 0.76% | 1,000,000 | CALL | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $8.1M | 0.76% | 1,200,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $7.9M | 0.74% | 2,900,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $7.6M | 0.71% | 500,000 | CALL | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $7.4M | 0.69% | 284,372 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $7.0M | 0.65% | 775,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $6.9M | 0.65% | 400,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $6.9M | 0.64% | 150,000 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $6.5M | 0.61% | 382,345 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $6.2M | 0.58% | 325,000 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HLDG INC | $5.8M | 0.54% | 200,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $5.6M | 0.52% | 1,660,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $4.9M | 0.46% | 2,000,000 | Common | SOLE |
| 45114M109 | — | ICOSAVAX INC | $4.7M | 0.44% | 300,000 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $4.4M | 0.41% | 600,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $4.4M | 0.41% | 500,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $4.2M | 0.40% | 307,076 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $4.2M | 0.39% | 544,960 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX INC | $3.8M | 0.35% | 100,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $3.2M | 0.30% | 150,000 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $2.6M | 0.25% | 150,000 | Common | SOLE |
| 24661P807 | DCTH | DELCATH SYS INC | $1.2M | 0.12% | 300,000 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $928,395 | 0.09% | 493,827 | Common | SOLE |
| 4525EP101 | VTLUSD | IMMUNIC INC | $631,776 | 0.06% | 421,184 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $4,000 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.